Unknown

Dataset Information

0

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.


ABSTRACT:

Background

Schizophrenia is associated with significant economic burden. In Brazil, antipsychotic drugs and outpatient and hospital services are provided by the Brazilian National Health System (SUS) for patients with schizophrenia. However, few studies capture the cost of managing these patients within the Brazilian NHS. This is important to appraise different management approaches within universal healthcare systems.

Objective

Our objective was to use real-world data to describe the costs associated with the treatment of schizophrenia in adults receiving atypical antipsychotics in Brazil from 2000 to 2010.

Methods

We integrated three national databases for adult patients with schizophrenia receiving one or more atypical antipsychotics. We assessed only direct medical costs and the study was conducted from a public-payer perspective. A multivariate log-linear regression model was performed to evaluate associations between costs and clinical and demographic variables.

Results

We identified 174,310 patients with schizophrenia, with mean ± standard deviation (SD) annual costs of $US1811.92 ± 284.39 per patient. Atypical antipsychotics accounted for 79.7% of total costs, with a mean annual cost per patient of $US1578.74 ± 240.40. Mean annual costs per patient were $US2482.90 ± 302.92 for psychiatric hospitalization and $US862.96 ± 160.18 for outpatient psychiatric care. Olanzapine was used by 47.7% of patients and represented 62.8% of the total costs of atypical antipsychotics. Patients who used clozapine had the highest mean annual cost per patient for outpatient psychiatric care and psychiatric hospitalization.

Conclusions

Atypical antipsychotics were responsible for the majority of the schizophrenia treatment costs, and psychiatric hospitalization costs were the highest mean annual cost per patient. Authorities should ensure efficient use of atypical antipsychotics and encourage outpatient psychiatric care over psychiatric hospitalization where possible.

SUBMITTER: Barbosa WB 

PROVIDER: S-EPMC6132453 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.

Barbosa Wallace Breno WB   Costa Juliana de Oliveira JO   de Lemos Lívia Lovato Pires LLP   Gomes Rosângela Maria RM   de Oliveira Helian Nunes HN   Ruas Cristina Mariano CM   Acurcio Francisco de Assis FA   Barbui Corrado C   Bennie Marion M   Godman Brian B   Guerra Augusto Afonso AA  

Applied health economics and health policy 20181001 5


<h4>Background</h4>Schizophrenia is associated with significant economic burden. In Brazil, antipsychotic drugs and outpatient and hospital services are provided by the Brazilian National Health System (SUS) for patients with schizophrenia. However, few studies capture the cost of managing these patients within the Brazilian NHS. This is important to appraise different management approaches within universal healthcare systems.<h4>Objective</h4>Our objective was to use real-world data to describe  ...[more]

Similar Datasets

| S-EPMC2846148 | biostudies-literature
| S-EPMC4164462 | biostudies-literature
| S-EPMC6473905 | biostudies-literature
| S-EPMC5831671 | biostudies-literature
| S-EPMC4622120 | biostudies-literature
| S-EPMC9500595 | biostudies-literature
| S-EPMC8185170 | biostudies-literature
| S-EPMC3722141 | biostudies-literature
| S-EPMC27538 | biostudies-literature
2020-06-01 | PXD015049 | Pride